{"id":"bromocriptine-qr","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Orthostatic hypotension"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bromocriptine acts as a dopamine agonist at D2 receptors in the tuberoinfundibular pathway, suppressing prolactin release from the anterior pituitary. The quick-release (QR) formulation is designed to provide rapid onset of action. Beyond prolactin suppression, bromocriptine has been investigated for effects on circadian rhythm and metabolic regulation, particularly in the context of cardiovascular and metabolic disease.","oneSentence":"Bromocriptine-QR is a quick-release formulation of bromocriptine, a dopamine D2 receptor agonist that reduces prolactin secretion and modulates circadian rhythm regulation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:41:59.818Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hyperprolactinemia"},{"name":"Prolactin-secreting pituitary adenoma (prolactinoma)"},{"name":"Cardiovascular risk reduction in type 2 diabetes (phase 3 indication)"}]},"trialDetails":[{"nctId":"NCT05405244","phase":"PHASE3","title":"Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2017-09-19","conditions":"Overweight and Obesity, Eating Behavior","enrollment":55},{"nctId":"NCT02682901","phase":"PHASE4","title":"Bromocriptine-QR Therapy on Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects","status":"COMPLETED","sponsor":"Eastern Virginia Medical School","startDate":"2015-10-05","conditions":"Diabetic Autonomic Neuropathy","enrollment":84},{"nctId":"NCT02544321","phase":"PHASE2","title":"Bromocriptine Quick Release (BCQR) as Adjunct Therapy in Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2015-09","conditions":"Type 1 Diabetes","enrollment":108},{"nctId":"NCT01474018","phase":"PHASE4","title":"QR-Bromocriptine as an Adjunct to Insulin and Metformin in the Treatment of Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2011-11","conditions":"Diabetes Mellitus, Type 2","enrollment":15},{"nctId":"NCT02299050","phase":"PHASE4","title":"Effect of Cycloset on Glycemic Control When Added to Glucagon-like Peptide 1 (GLP-1) Analogue Therapy","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2014-06","conditions":"Type 2 Diabetes","enrollment":23},{"nctId":"NCT02078440","phase":"PHASE1","title":"Pharmacokinetic Study of CYCLOSET ® 0.8 mg Tablets in Children and Adolescent Type 2 Diabetes Mellitus Subjects","status":"COMPLETED","sponsor":"VeroScience","startDate":"2014-01","conditions":"Type 2 Diabetes","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["quick-release (QR) bromocriptine (cycloset)"],"phase":"phase_3","status":"active","brandName":"Bromocriptine-QR","genericName":"Bromocriptine-QR","companyName":"University of North Carolina, Chapel Hill","companyId":"university-of-north-carolina-chapel-hill","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bromocriptine-QR is a quick-release formulation of bromocriptine, a dopamine D2 receptor agonist that reduces prolactin secretion and modulates circadian rhythm regulation. Used for Hyperprolactinemia, Prolactin-secreting pituitary adenoma (prolactinoma), Cardiovascular risk reduction in type 2 diabetes (phase 3 indication).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}